Inquiry

Analysis of IBD Immunopathogenesis

The etiology of inflammatory bowel disease (IBD) is unclear, but IBD seems to survive in genetically predisposed populations because of compromised immune responses to gut microbes. This aberrant immune response is connected to dysregulated innate and adaptive immune responses with profound effects on intestinal inflammation. We can only really get a handle on IBD when all of the potential immune components and their interactions are known and mapped out in full. There’s also more research to be done on immune components’ contribution to intestinal immunity to develop better therapies for IBD.

Fig. 1. The intricate universe of immune and nonimmune components involved in IBD immunopathogenesis. (De Souza et al., 2016)

IBD Immunopathogenesis Analysis Services

At Ace Therapeutics, we provide comprehensive IBD immunopathogenesis analysis services to pharmaceutical and biotech companies. Combining advanced technology and specialized knowledge, our team of experts focuses on studying the complex interactions between immune factors and IBD. We aim to help our clients gain insights into the immune mechanisms of IBD, discover potential therapeutic targets, and develop novel biological therapies for IBD.

We can determine exact molecular causes for the immunopathogenesis of IBD by uncovering novel immunogenetic parameters, defining heterogeneity parameters, and making detailed multiparametric measurements of different aspects of elucidated disease biology. Thanks to these broad-based tools, we can assist our clients to learn about the whole picture of IBD immunopathogenesis.

Development of Biological Therapies for IBD

We focus on the innate and adaptive gut immune mechanisms of IBD to help our clients develop novel targeting strategies to inhibit or modulate excessive gut immune responses and potentially reverse mucosal inflammation. We provide data from animal and experimental studies as supporting evidence.

• Therapies targeting cytokines (e.g., IL-22, IL-6, IL-12/IL-23, IL-17, IL-10, IL-1β/IL-18, TNF)
• Therapies targeting chemokines (e.g., IL-8, CCL2, CCL3, CCL4, CCL7, CCL20, CXCL5, CXCL8, CXCL10)
• IBD therapies targeting Th17
• IBD therapies targeting ILC
• Inhibition of lymphoid cell homing
• Inhibition of IBD-related lymphoid cell survival
• Targeting epithelial cells
• Targeting B cells
• Enhancing innate immunity as a therapeutic target of IBD

Ace Therapeutics offers dependable services to assist clients in analyzing immune mechanisms related to IBD and developing innovative biological therapies. We collaborate closely with our clients to deliver tailored solutions that address the specific needs of each research project. If you are interested in our services, please do not hesitate to contact us.